Main results
We included two RCTs with a total of 121 participants. Both RCTs were of short-term parenteral anticoagulation early after ICH: one tested heparin and the other enoxaparin. The risk of bias in the included RCTs was generally unclear or low, with the exception of blinding of participants and personnel, which was not done. The included RCTs did not report our chosen primary outcome (a composite outcome of all serious vascular events including ischaemic stroke, myocardial infarction, other major ischaemic event, ICH, major extracerebral haemorrhage, and vascular death). Parenteral anticoagulation did not cause a statistically significant difference in case fatality (RR 1.25, 95% confidence interval (CI) 0.38 to 4.07 in one RCT involving 46 participants, low-quality evidence), ICH, or major extracerebral haemorrhage (no detected events in one RCT involving 75 participants, low-quality evidence), growth of ICH (RR 1.64, 95% CI 0.51 to 5.29 in two RCTs involving 121 participants, low-quality evidence), deep vein thrombosis (RR 0.99, 95% CI 0.49 to 1.96 in two RCTs involving 121 participants, low quality evidence), or major ischaemic events (RR 0.54, 95% CI 0.23 to 1.28 in two RCTs involving 121 participants, low quality evidence).
Authors' conclusions
There is insufficient evidence from RCTs to support or discourage the use of antithrombotic treatment after ICH. RCTs comparing starting versus avoiding antiplatelet or anticoagulant drugs after ICH appear justified and are needed in clinical practice.
P L A I N L A N G U A G E S U M M A R Y

Drugs to prevent clots after bleeding in the brain
Review question
What is the effectiveness and safety of medications used to prevent clots (antithrombotic treatments) both in the early stages and longterm in people who have had a bleed within their brain (intracerebral haemorrhage)?
Background
People with stroke due to bleeding in the brain (also known as intracerebral haemorrhage: ICH) are more likely to develop clots in their blood vessels due to immobility (in the early stages) and due to other medical conditions (in the long term). Blood clots in the lungs, brain, or other organs can cause serious illness or death. Drugs that prevent clots (also known as 'antithrombotic drugs') might be useful to stop clot formation in people with ICH. However, these drugs can also cause serious bleeding complications.
Study characteristics
From extensive searches conducted on 8 March 2017, we identified two relevant randomised controlled trials (RCTs), which are the fairest tests of treatment. There were 121 participants in these two trials, which compared blood-thinning 'anticoagulant' drugs (heparin in one and enoxaparin in the other) delivered by injections under the skin versus no anticoagulant drug soon after ICH.
Key results
The primary outcome of this review was the combined risk of several important clinical outcome events (such as another intracerebral haemorrhage, ischaemic stroke, or death from a cardiovascular cause). We were not able to calculate this outcome for the included studies. Neither RCT reported on recovery of independence or mental abilities. One RCT involving 46 participants reported on case fatality associated with short-term antithrombotic treatment, and did not find a statistically meaningful effect. For the consequences of treatment that could be analysed, the risk estimates were imprecise and uncertain. Therefore, the potential benefits and harms of antithrombotic drugs soon after a stroke due to bleeding in the brain remain unclear. New high-quality RCTs investigating the use of antithrombotic treatment after stroke due to ICH appear justified and are needed.
Quality of the evidence
The overall quality of the evidence was low. This is due to the way the included trials were conducted and reported, as well as the small number of participants, which may not have been high enough to detect small differences between the antithrombotic treatment and no antithrombotic treatment groups. * The risk in the intervention group (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its 95% CI).
Outcomes
CI: Conf idence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence High quality: We are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ect M oderate quality: We are m oderately conf ident in the ef f ect estim ate: The true ef f ect is likely to be close to the estim ate of the ef f ect, but there is a possibility that it is substantially dif f erent Low quality: Our conf idence in the ef f ect estim ate is lim ited: The true ef f ect m ay be substantially dif f erent f rom the estim ate of the ef f ect Very low quality: We have very little conf idence in the ef f ect estim ate: The true ef f ect is likely to be substantially dif f erent f rom the estim ate of ef f ect They are also at risk of ischaemic stroke, ischaemic heart disease, atrial fibrillation, and systemic embolism. A review of observational studies found that the annual risk of recurrent ICH was between 1.8% and 7.4% (Poon 2014). Three studies compared outcomes after ICH in different locations within the brain, two of which found that the risk of recurrence after lobar ICH appeared higher than after deep ICH (Poon 2014). Most patients in the world have ICH diagnosis and location confirmed by computed tomography (CT). However, some patients have magnetic resonance imaging (MRI), on which brain microbleeds are biomarkers of a higher risk of both recurrent ischaemic stroke and ICH (Cordonnier 2007; Wilson 2016) . In studies that quantified the risks of both recurrent ICH and ischaemic stroke after ICH, these risks appeared similar (Poon 2014).
B A C K G R O U N D Description of the condition
Description of the intervention
Antithrombotic (anticoagulant and antiplatelet) drugs are effective for preventing thrombosis and embolism of clots in the brain, heart, limbs, and lungs. However, their effects are unknown in people who also have a past history of ICH, because they were excluded from the RCTs that demonstrated the benefits of antithrombotic drugs. There is uncertainty about whether to start these drugs after ICH (Al-Shahi Salman 2014; Falcone 2014; Molina 2011; Steiner 2011 
O B J E C T I V E S Primary objective
To determine the overall effectiveness and safety of antithrombotic drugs for people with ICH.
Secondary objective
To determine whether the effectiveness and safety of antithrombotic treatment differs in prespecified subgroups (see Subgroup analysis and investigation of heterogeneity).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We sought all RCTs that made comparisons of starting versus avoiding antithrombotic drugs, or direct comparisons of different classes of antithrombotic drugs, for preventing thromboembolism after ICH. We included RCTs published in any language and planned to arrange translation where the language of publication was not English.
Types of participants
We sought RCTs whose participants survived a spontaneous ICH that had been diagnosed by CT or MRI. We included RCTs whether or not they had taken antithrombotic drugs at the time of ICH.
Types of interventions
We sought RCTs that compared the use of any antithrombotic drug against no antithrombotic treatment, as well as RCTs that compared different antithrombotic drugs. We placed no constraints on dosage, route of administration, or duration of administration. We separated RCTs investigating short-term treatment (for example, with low-molecular-weight heparin or unfractionated heparin in the acute post-stroke phase) and those investigating long-term treatment (for example, with oral anticoagulants or antiplatelets). We excluded RCTs in which the effects of antithrombotic drugs might have been confounded by the administration of another active drug to participants (e.g. if allocation to this additional treatment was not evenly distributed between groups in an RCT, or was not randomly allocated).
Types of outcome measures
Primary outcomes
• Composite outcome of 'all serious vascular events' (ischaemic stroke, myocardial infarction, other major ischaemic event, ICH, major extracerebral haemorrhage, and vascular death) during the scheduled follow-up period.
Secondary outcomes
• Death during the scheduled follow-up period.
• The individual components of the composite vascular outcome: ischaemic stroke, myocardial infarction, other major ischaemic event, ICH, major extracerebral haemorrhage, and vascular death.
• Growth of ICH.
• Deep vein thrombosis.
• Functional status (where measured using validated scales) at the end of the scheduled follow-up period.
• Cognitive status (where measured using validated scales) at the end of the scheduled follow-up period.
Search methods for identification of studies
See the 'Specialized register' section in the Cochrane Stroke Group module. We searched for RCTs in any language and planned to arrange for the translation of relevant articles where necessary.
Electronic searches
We searched the Cochrane Stroke Group trials register in March 2017 and the following electronic databases, using search strategies that the Cochrane Stroke Group's Information Specialist helped us design:
• 
Searching other resources
We screened the reference lists of relevant studies to identify further studies for potential inclusion in the review. We also used the Science Citation Index Cited Reference Search for forward tracking of relevant articles.
Three review authors (LAP, JB, EF) independently screened the titles and abstracts of the references obtained as a result of our searching activities, and excluded reports that were obviously irrelevant. We retrieved full-text articles for the remaining references, and the same three review authors independently screened these full-text articles to identify studies for inclusion, and identified and recorded reasons for the exclusion of ineligible studies. We resolved any disagreements through discussion or, if required, we planned on consulting a fourth review author (EB). We collated multiple reports of the same study so that each study, not each reference, is the unit of interest in the review. We recorded the selection process and completed a PRISMA flow diagram (See Figure  1 in the Results of the search section).
Data extraction and management
Three review authors (LAP, JB, EF) independently extracted data from included studies using a preformulated data collection form.
Assessment of risk of bias in included studies
Three review authors (LAP, JB, EF) independently assessed risks of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We resolved any disagreements by discussion or by involving another review author (EB). We assessed the risks of bias according to the following domains.
• Random sequence generation We graded the risk of bias for each domain as high, low or unclear and provide information from the study report, together with a justification for our judgement, in the 'Risk of bias' tables.
Measures of treatment effect
We intended to:
• convert categorical estimates of effect to the risk ratio (RR) or odds ratio (OR), if required;
• express measures of survival as a hazard ratio (HR); and • use summary measures obtained from univariate or, where RCTs used the same covariates for adjustment, multivariable analyses.
Unit of analysis issues
Repeated observations on participants
We planned to analyse functional and cognitive status at end of follow-up, and not to use repeat observations during follow-up. If one RCT (or only a few RCTs) had a much longer period of followup than the majority of RCTs (for example, two years compared with six months in the majority of trials) we intended to perform a sensitivity analysis using the six-month observations from all RCTs.
Events that may recur
We analysed the first event in all participants, and not later events.
Multiple intervention groups
Where a RCT contained multiple treatment groups that were all compared with just one control group, we intended to ensure that the placebo group was shared between the multiple treatment groups by dividing it into the appropriate number of subgroups and conducting separate, independent comparisons.
Dealing with missing data
We contacted RCT authors for unpublished data if relevant data were missing. If only a minority (less than half ) of data were missing, we planned to ignore the missing data and perform a 'complete set analysis'. If more substantial amounts of data were missing, and there was a chance that data were not missing at random, we planned to perform sensitivity analyses assuming both a bestcase and a worst-case scenario, or apply statistical imputation or models, or both, to account for the missing data. A best-case scenario meant that we assumed that all missing data in the intervention group represent good outcomes and all missing data in the control group represent poor outcomes. A worst-case scenario meant that we assumed that all missing data in the intervention group represent poor outcomes and all missing data in the control group represent good outcomes.
Assessment of heterogeneity
We investigated inconsistency between included RCTs using the I 2 statistic. We interpreted this value using the guide provided in Chapter 9.5.2 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011):
• 0% to 40%: might not be important • 30% to 60%: may represent moderate heterogeneity • 50% to 90%: may represent substantial heterogeneity • 75% to 100%: represents considerable heterogeneity
If we observed substantial inconsistency in our data, we intended to use sensitivity analysis to elucidate which factors might explain the inconsistency.
Assessment of reporting biases
We included all published and unpublished data and secondary publications from RCTs. If we included a sufficient number of RCTs (more than 10), we planned to assess the likelihood of reporting biases through the use of a funnel plot.
Data synthesis
If RCTs were sufficiently similar, we planned to conduct a metaanalysis by pooling the appropriate data using Review Manager 5 (RevMan 2014). We planned to calculate the risk ratio (RR), odds ratio (OR), or hazard ratio (HR) for each outcome from data extracted from included RCTs using the Peto fixed-effect method, or a random-effects model if there was significant heterogeneity between RCTs. We defined significant heterogeneity as substantial clinical or methodological diversity between RCTs such that the true effect measure is no longer uniform.
'Summary of findings' table
We created a 'Summary of findings' table using the GRADEpro Guideline Development Tool (GRADEpro GDT), and included the following outcomes for short-term antithrombotic treatment: the composite outcome of all serious vascular events, death, growth of ICH, ICH, major extracerebral haemorrhage, deep vein thrombosis, other major ischaemic events, functional status, and cognitive status. We planned a 'Summary of findings' table for longterm antithrombotic treatment which included the following outcomes: the composite outcome of all serious vascular events, death, functional status, and cognitive status. Two review authors (LAP, JB) independently classified the quality of the evidence as being 'high', 'moderate', 'low', or 'very low', based on the presence and extent of the following five criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011):
• Limitations in the design and implementation of the contributing trials
• Indirectness of evidence • Unexplained heterogeneity or inconsistency of results • Imprecision of results • High probability of publication bias
We provided justification in the footnotes when we downgraded the quality from 'high'.
Subgroup analysis and investigation of heterogeneity
We planned to perform the following subgroup analyses, if possible.
• Participants with different age, sex, and stroke severity • Different classes of antithrombotic drugs • Different intensities of antithrombotic treatment
• Different times of starting treatment (e.g. within one month of ICH versus later, or within 10 to 30 weeks or later)
• Participants who were on antithrombotic treatment before ICH (re-starters) versus participants who were not receiving these treatments (starters)
• Different levels of risk for future ischaemic events (for example, because of differences in age, sex, history of hypertension, history of atrial fibrillation (with further stratification by the CHA 2 DS 2 -Vasc score))
• Different levels of risk for future ICH • Biomarkers of bleeding or clotting risk on brain CT or MRI (e.g. brain microbleeds on MRI)
Sensitivity analysis
If the results were heterogeneous, we planned to use sensitivity analysis to investigate how the results differed when we excluded RCTs that were found to have a high risk of bias. We planned to perform other sensitivity analyses to explore reasons for heterogeneity, for example, where there is an active therapy other than an antithrombotic drug that is not balanced by the randomisation process.
R E S U L T S Description of studies
We included two RCTs (see Included studies), excluded seven RCTs (see Excluded studies), and identified seven ongoing RCTs (see Ongoing studies). For comprehensive tabulated descriptions of included, excluded, and ongoing studies please refer to Characteristics of included studies, Characteristics of excluded studies, and Characteristics of ongoing studies.
Results of the search
Our searches of CENTRAL, Embase, and OVID MEDLINE identified 331, 2557, and 850 potentially relevant records, respectively. Automated de-duplication identified 904 redundant records, leaving 2834 unique and potentially relevant records. We screened the titles and abstracts of these 2834 records and assessed the full texts of nine relevant records for inclusion (Boeer 1991; CAST 1997; Dickmann 1988; Frontera 2014; IST 1997; Li 2013; Orken 2009; Venturelli 2014; Yan 2014) . We included two RCTs in our review (Dickmann 1988; Orken 2009) . A reference search of included RCTs yielded no further relevant records. See Figure  1 for a graphical representation of our search.
The search of trials registries for ongoing RCTs identified three relevant RCTs: APACHE-AF; PICASSO; RESTART, and we were aware of four additional RCTs from personal communication with investigators (NASPAF-ICH; RESTART Nord de France; SoSTART; STATICH).
Included studies
Dickmann 1988 was a German single-centre study that excluded patients if they had a bleeding diathesis, a sustained diastolic blood pressure higher than 120 mmHg or were in deep coma with signs of brain herniation, and retained 46 participants for inclusion. Orken 2009 was a Turkish single-centre study that started with 110 ICH patients and applied the following exclusion criteria: early death before heparin treatment (n = 13), death before day 7 investigations (n = 4), secondary ICH due to aneurysm, arteriovenous malformations, trauma, or tumour (n = 11), excessive anticoagulation (International normalised ratio (INR) > 2.0) (n = 5), and contraindication to contrast media (n = 2). This left 75 participants for inclusion. Both of the included RCTs included participants with ICH diagnosed by CT. Orken 2009 specified that these were primary ICH, whereas Dickmann 1988 did not specify the type of ICH included. Dickmann 1988 used 5000 units of heparin (Liquemin-Roche) delivered subcutaneously every eight hours starting at day four after ICH. Orken 2009 used 40 mg/day of enoxaparin sodium delivered subcutaneously after the first 48 hours from ICH onset. The intervention and comparator groups of both RCTs received graduated compression stockings. Dickmann 1988 reported on other major ischaemic events, and vascular death from other causes, although did not specifically define these outcomes. Orken 2009 reported on other major ischaemic events, ICH, and major extracerebral haemorrhage. Both of the included RCTs provided shortterm outcome data only. Dickmann 1988 had a follow-up period of 10 days and Orken 2009 had a follow-up period of 21 days.
Excluded studies
We excluded seven studies for not meeting the inclusion criteria of this review after having screened their full texts. Boeer 1991 was an extension phase of Dickmann 1988 and randomisation was not described, leading to its exclusion from this review. CAST 1997 and IST 1997 were two RCTs investigating the use of antiplatelet treatment after acute ischaemic stroke, and included several hundred participants with ICH who were randomised before CT had been performed to establish the pathological sub-type of stroke. Data on the ICH sub-population of these studies were reported in a systematic review (Keir 2002 ) and the individual patient data from IST 1997 (Sandercock 2011). These sources reported that this population included primary ICH (52%) and haemorrhagic transformation of ischaemic stroke (48%), but unfortunately the chief investigator informed us that it would be impossible to isolate the participants with primary ICH (IST 1997). Frontera 2014 was excluded because it was not randomised. Li 2013 assessed transfusion of frozen apheresis platelets in patients with ICH and on aspirin. Venturelli 2014 was a post hoc analysis of a RCT in which antithrombotic treatment was not randomly assigned, making this analysis observational in nature. Yan 2014 included a population of patients with and without cerebral microbleeds after acute ischaemic stroke.
Risk of bias in included studies
We assessed risks of bias for both included RCTs 
Allocation
Both Dickmann 1988 and Orken 2009 were reported to be randomised but neither RCT described the method of randomisation, and neither RCT described the method of allocation concealment. We therefore determined both RCTs to be at unclear risk of selection bias.
Blinding
Due to the nature of the intervention (subcutaneous injection), and lack of placebo, blinding of participants and the personnel delivering the intervention was not possible. Both Dickmann 1988 and Orken 2009 were therefore at high risk of performance bias. Dickmann 1988 explicitly mentioned blinding of outcome raters and was at low risk of detection bias. Orken 2009 reported that radiologists were blinded to the clinical baseline radiological findings, but did not explicitly mention blinding of treatment allocation and was therefore at unclear risk of detection bias. Outcome data were complete in both included RCTs, which were both rated at low risk of attrition bias.
Selective reporting
Both Dickmann 1988 and Orken 2009 reported all outcomes planned in their respective Methods sections, and each reported most expected outcomes of interest. Both included RCTs were therefore at low risk of reporting bias.
Other potential sources of bias
Neither Dickmann 1988 nor Orken 2009 described conflicts of interest or sources of funding. Neither study was prospectively registered. Both were therefore at an unclear risk of other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison Antithrombotic treatment compared to no antithrombotic treatment for intracerebral haemorrhage
Short-term antithrombotic treatment
We included two RCTs for this comparison (Dickmann 1988; Orken 2009). We were able to extract numerical data on some of the relevant outcomes.
Composite outcome of all serious vascular events
We were unable to calculate the composite vascular endpoint for either Dickmann 1988 or Orken 2009 (Analysis 1.1).
Death
Only one RCT reported death from all causes (Dickmann 1988) . The causes of death in this RCT were rebleeding (4), bronchopneumonia (4), and heart failure (1). There was no statistically significant difference between the intervention and control groups for this outcome (risk ratio (RR) 1.25, 95% confidence interval (CI) 0.38 to 4.07; Analysis 1.2; 46 participants).
Vascular death
Only one RCT reported deaths, but it did not adequately report in which group (control/intervention) instances of death from bronchopneumonia (4) and heart failure (1) occurred (Dickmann 1988) . Because death from heart failure constitutes a vascular death and it was unclear in which group this death occurred, we were unable to include data for this outcome. However, it was reported that three deaths from expansion of the haematoma occurred in the control group and one such death occurred in the intervention group.
Ischaemic stroke
This outcome was not reported by either Dickmann 1988 or Orken 2009.
Myocardial infarction
Other major ischaemic event
Both included RCTs reported other major ischaemic events (Dickmann 1988; Orken 2009 ). All events for this outcome were pulmonary embolism detected by CT pulmonary angiogram (Orken 2009) or lung perfusion scintigraphy (Dickmann 1988). We combined results in a meta-analysis (Analysis 1.6), and detected no statistically significant difference between groups (RR 0.54, 95% CI 0.23 to 1.28; 121 participants). The results of this analysis are limited by the different methods of detecting pulmonary emboli used by each study group.
Intracerebral haemorrhage
One RCT involving 75 participants reported this outcome (Orken 2009). There were no recorded events in either group.
Major extracerebral haemorrhage
Growth of ICH
Both of the included studies reported on ICH growth. Dickmann 1988 had an ambiguous definition for this outcome, 'rebleeding', which we considered to refer to ICH growth (whether this was due to continued bleeding, or recurrent ICH after cessation of the first ICH). This study did not describe a threshold of increased volume above which ICH growth was deemed to occur, and conducted brain CTs on days 1, 6, and 10 after ICH. Orken 2009 defined ICH growth as an increase in volume on CT of more than 33% or more than 12.5 mL using the ABC/2 method (Kothari 1996), and checked for this outcome on follow-up brain CTs at 24 hours, 72 hours, day 7, and day 21 after ICH. We combined the results from these two RCTs in a meta-analysis (Analysis 1.9), and observed no statistically significant differences between groups (RR 1.64, 95% CI 0.51 to 5.29; 121 participants).
Deep vein thrombosis
Both included studies reported on the outcome of deep vein thrombosis (DVT). All events for this outcome were DVT detected by phleboscintigraphy at days 2 and 10 (Dickmann 1988) or by venous doppler ultrasound examination on day 7 (Orken 2009). All events reported in Orken 2009 were asymptomatic, whereas Dickmann 1988 did not specify whether events were symptomatic or not. We detected no statistically significant difference between groups for this outcome (RR 0.99, 95% CI 0.49 to 1.96; Analysis 1.10; 121 participants). 
Long-term antithrombotic treatment
We did not find any completed RCTs that investigated long-term antithrombotic treatment.
D I S C U S S I O N
Summary of main results
We found some evidence on the short-term effects of antithrombotic drugs after ICH in two RCTs (Dickmann 1988; Orken 2009 ), but no evidence on the effects of long-term antithrombotic treatment. We were unable to calculate the composite primary outcome of all serious vascular events due to incompleteness of reporting of the component outcomes in the included RCTs (Dickmann 1988; Orken 2009 ). None of the outcomes reported showed a statistically significant difference between groups, possibly because the two included RCTs were inadequately powered to detect significant differences for our outcomes. Neither included RCT reported outcomes for ischaemic stroke, myocardial infarction, functional status, or cognitive status. We were unable to extract data on any prespecified subgroups.
Overall completeness and applicability of evidence
The evidence available from completed RCTs of short-term antithrombotic drug treatment after ICH is sparse. Data from the two included RCTs contribute moderately applicable evidence to this field; their inclusion criteria and settings are representative of typical ICH patients. The applicability of Dickmann 1988 is somewhat limited by waiting to start treatment until after day four following ICH onset; one implication might be that some of the potential effects of subcutaneous heparin, for example those on ICH growth, never manifested. There is no comparative evidence on the differences between distinct types of anticoagulants used in this setting. Dickmann 1988 investigated the effects of heparin, whereas Orken 2009 used enoxaparin sodium, a low-molecularweight heparin. However, we were encouraged to find that there are seven ongoing RCTs investigating long-term antithrombotic treatment after ICH (APACHE-AF; PICASSO; NASPAF-ICH; RESTART; RESTART Nord de France; SoSTART; STATICH).
Quality of the evidence
The methodological quality of the included RCTs was limited by randomisation and allocation concealment not being described, failure to blind participants, and the optimal information size criterion not being met. The overall quality of evidence was therefore low. Both studies, despite investigating different drugs and starting treatment at different times, found no statistically significant difference between groups for outcomes relevant to this review. It is possible that this is due to these RCTs being inadequately powered to detect statistically meaningful differences, rather than there being no effect of the interventions.
Potential biases in the review process
None identified.
Agreements and disagreements with other studies or reviews
We identified two systematic reviews on short-term antithrombotic treatment (Keir 2002; Paciaroni 2011) . Keir 2002 included data from three RCTs (CAST 1997; Dickmann 1988; IST 1997) and included individual patient data from IST 1997 and CAST 1997 on participants with both primary ICH (52%) as well as haemorrhagic transformation of ischaemic infarcts (48%), but did not describe results for these groups separately. Keir 2002 preceded Orken 2009, a study which we included in this review. The second systematic review we identified included non-randomised controlled studies (Paciaroni 2011). The non-randomised studies included in this review were Wasay 2008 and Tetri 2008. This review concluded that early antithrombotic treatment was associated with a significant reduction in pulmonary embolism, a nonsignificant reduction in mortality, and a non-significant increase in haemorrhagic expansion (Paciaroni 2011). We identified one systematic review on long-term antithrombotic use after ICH, but it could not draw any conclusions from the two epidemiological studies and several case series that it included (Flynn 2010b).
A U T H O R S ' C O N C L U S I O N S Implications for practice
The available evidence from two RCTs of short-term parenteral anticoagulation after ICH neither support nor discourage the use of short-term antithrombotic treatment after ICH.
There are no published RCTs on long-term antithrombotic treatment after ICH, but seven RCTs are ongoing at the time of this review.
At the present time, clinicians will have to use other sources of information to support clinical judgements.
Implications for research
Research on the use of antithrombotic drugs after ICH represents an area of unmet need for patients, clinicians, and other consumers. These data suggest that further high-quality RCTs are needed. For short-term antithrombotic use, future studies should consider functional outcome and quality of life in addition to clinical outcomes, such as ischaemic events, haemorrhagic events, or death. For long-term antithrombotic use, future RCTs should consider investigating the relative effectiveness and safety of different antithrombotic drugs, for example warfarin, aspirin, and the direct oral anticoagulants.
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R E F E R E N C E S
References to studies included in this review
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Frontera 2014 This is a controlled clinical trial that was not randomised.
IST 1997
This trial included several hundred participants with ICH who were randomised prior to CT. These data were not available in the original manuscript. We had hoped that data from the Keir 2002 systematic review or the published individual data forms (Sandercock 2011) would yield useable data for this review, but Keir 2002 did not report primary ICH separately from haemorrhagic expansion of an acute ischaemic stroke, and after contacting the chief investigator of IST 1997 we discovered that it was not possible to extract data on primary ICH separately
Li 2013
The intervention randomised in this study is transfusion of frozen apheresis platelets in participants on aspirin and with ICH
Venturelli 2014 This is a post hoc analysis of the INTERACT2 trial. The intervention that is the subject of this analysis, prophylactic subcutaneous heparin after ICH, was not randomly assigned in INTERACT2. Therefore, this analysis is observational in nature
Yan 2014
The participant group did not have primary ICH; it was a cohort of people with and without cerebral microbleeds and haemorrhagic transformation, with acute ischaemic stroke following rtPA treatment CT: computed tomography ICH: intracerebral haemorrhage rtPA: Recombinant tissue plasminogen activator
Characteristics of ongoing studies [ordered by study ID]
APACHE-AF
Trial name or title Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation (APACHE-AF) • Non-stroke indication for antiplatelet or anticoagulant therapy • Estimated creatinine clearance of < 30 ml per minute • Platelet count less than 100,000/mm 3 at enrolment or other bleeding diathesis • Uncontrollable hypertension with SBP/DBP consistently above 160/100 mmHg • Prior symptomatic lobar ICH other than the qualifying event (i.e. ≥ 2 symptomatic lobar ICH)
• Known hypersensitivity to either aspirin or NOACs • Pregnant or breastfeeding
NASPAF-ICH (Continued)
Interventions Non-vitamin K oral antagonist (agent at the discretion of the local investigator) vs aspirin 81 mg Strict long-term blood pressure control to target of < 130/80 mmHg for all participants Outcomes Primary outcome measure: the primary feasibility outcome will be recruitment rates Secondary outcomes will be refusal rates and retention rates 
RESTART (Continued)
• Spontaneous primary or secondary ICH.
• Patient had taken antithrombotic drug(s) for the prevention of vaso-occlusive disease before ICH onset. Randomisation > 24 hours after ICH onset.
• Patient and their doctor are uncertain about whether to start or avoid antiplatelet drugs.
• Patient is registered with a general practitioner (GP).
• Brain imaging that first diagnosed the ICH is available.
• Participant or representative consent. Exclusion criteria:
• ICH due to preceding trauma or haemorrhagic transformation of ischaemic stroke.
• Patient is taking an anticoagulant drug following ICH.
• Patient is pregnant, breastfeeding, or of childbearing age and not taking contraception.
• Patient is being treated or followed up in another CTIMP.
• Patient and carer unable to understand spoken or written English. Brain magnetic resonance imaging (MRI) sub-study: MRI done after ICH but before randomisation. No claustrophobia. MRI not contraindicated
Interventions
Participants will be randomised to either 'start antiplatelet medication' (restricted to the use of 1 or more of aspirin, dipyridamole or clopidogrel at the investigator's discretion) or "avoid antiplatelet medication" Outcomes Primary outcome measure: recurrent symptomatic ICH Secondary outcome measures:
• possible recurrent ICH;
• symptomatic non-fatal extracerebral haemorrhage, extracranial haemorrhage, and vaso-occlusive events; death;
• modified Rankin Scale score;
• adherence to antiplatelet drug(s) 
S O U R C E S O F S U P P O R T Internal sources
• No sources of support supplied
External sources
• Medical Research Council, UK. Senior clinical fellowship to RA-SS
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
We separately grouped RCTs investigating short-term and long-term treatment, instead of performing subgroup analyses as our protocol had specified.
We added two new outcomes: deep vein thrombosis and ICH growth, as we believe that they are of potential interest to consumers of this review. The addition of the outcome deep vein thrombosis allowed us to include it as a secondary outcome in this review without including it in another category (e.g. major ischaemic events). The addition of the ICH growth outcome is relevant to short-term antithrombotic treatment and was considered after we decided to divide our analysis into two groups according to the duration of antithrombotic drug use. The addition of these new outcomes did not result in any additional RCTs being included in this review.
We optimised the 'Summary of findings' tables to better reflect the outcomes of interest related to short-and long-term treatment. 
